TriangleNCT02000427 · OUTCOME
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to the data cut-of date of 20 May 2015; Maximum duration on study was 14.5 months.
What was measured
Participants who achieved remission (CR/CRh\*) during the first 2 cycles of treatment and received an allogeneic HSCT.
Analysis population: Participants who received an infusion of blinatumomab and had a CR/CRh\* response during the first 2 cycles of treatment.
Groups in this outcome
Blinatumomab
Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieved a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab. The initial dose was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 and for all subsequent cycles of treatment.
| Group | Source count |
|---|---|
| Blinatumomab | 16 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Blinatumomab | 43.8 | Not reported | 19.8 | 70.1 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 19.8
- upper Limit
- 70.1
- value
- 43.8
- denoms
- counts
- group Id
- OG000
- value
- 16
- units
- Participants
- description
- Participants who achieved remission (CR/CRh\*) during the first 2 cycles of treatment and received an allogeneic HSCT.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieved a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab. The initial dose was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 and for all subsequent cycles of treatment.
- id
- OG000
- title
- Blinatumomab
- param Type
- NUMBER
- population Description
- Participants who received an infusion of blinatumomab and had a CR/CRh\* response during the first 2 cycles of treatment.
- reporting Status
- POSTED
- time Frame
- Up to the data cut-of date of 20 May 2015; Maximum duration on study was 14.5 months.
- title
- Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice